Development

DPTX3186 Phase 1 Trial Targets Wnt Pathway in Advanced Solid Tumor Treatment

Edited by Robert McTiernan··2 min read

Novel Wnt Pathway Inhibitor Enters First-in-Human Trial for Solid Tumors

Researchers have initiated a first-in-human clinical trial for DPTX3186, a novel molecular intervention targeting the Wnt signaling pathway in patients with advanced solid tumors. The Phase 1 trial, currently recruiting at NEXT Oncology sites, represents an early-stage investigation into a potentially innovative approach for treating cancer with Wnt pathway activation.

The trial will explore DPTX3186's safety, tolerability, and preliminary efficacy across multiple solid tumor types, including colorectal, gastric, lung, and triple-negative breast cancers. Designed as an open-label, dose-escalation study, the protocol involves an oral medication regimen of 4 days on, 3 days off in a 28-day treatment cycle. While the specific sponsoring organization remains undisclosed, the study is being conducted at clinical sites in Fairfax, Virginia, and San Antonio, Texas.

Research Context

The Wnt signaling pathway plays a critical role in cellular proliferation and cancer progression, making it an increasingly attractive therapeutic target. Recent developments in the field suggest a renewed interest in direct Wnt/β-catenin inhibitors, following earlier challenges with upstream pathway modulators.

The AllSci BriefSystematic R&D and deal news. Daily.

The current landscape of Wnt pathway inhibitors includes several emerging molecules, such as:

  • Sapience Therapeutics' ST316, a β-catenin antagonist in Phase 1/2 trials
  • Parabilis Medicines' FOG-001, another early-stage solid tumor intervention
  • Ikena Oncology's IK-930, targeting the Hippo pathway

These trials reflect a growing recognition of the Wnt pathway's potential as a therapeutic target, particularly in treatment-resistant solid tumors. The DPTX3186 trial adds to this emerging body of research, focusing on patients with no standard treatment options and tumors characterized by Wnt pathway activation.

The trial's design acknowledges the complexity of targeting the Wnt pathway, employing a careful dose-escalation approach to understand the molecule's safety and potential efficacy. By investigating multiple solid tumor types, the study aims to provide broader insights into DPTX3186's therapeutic potential.

As the first clinical investigation of this molecule, the trial represents a critical step in potentially developing a new therapeutic approach for patients with limited treatment options.

Spot something wrong? Report an issue with this article